Pixel based SHG probes of extracellular matrix (ECM) alterations in ovarian cancer (Conference Presentation)

2017 ◽  
Author(s):  
Kirby R. Campbell ◽  
Rajeev Chaudhary ◽  
Julia Handel ◽  
Paul J. Campagnola
Keyword(s):  
Ovarian Cancer ◽  
Extracellular Matrix

scholarly journals Extracellular Matrix Proteins Expression Profiling in Chemoresistant Variants of the A2780 Ovarian Cancer Cell Line

2014 ◽  
Vol 2014 ◽  
pp. 1-9 ◽  
Author(s):  
Radosław Januchowski ◽  
Piotr Zawierucha ◽  
Marcin Ruciński ◽  
Michał Nowicki ◽  
Maciej Zabel
Keyword(s):  
Ovarian Cancer ◽  
Extracellular Matrix ◽  
Drug Resistance ◽  
Cell Line ◽  
Cancer Cell ◽  
Ovarian Cancer Cell ◽  
Ovarian Cancer Cell Line ◽  
Cancer Cell Line ◽  
Altered Expression ◽  
Expression Levels

Ovarian cancer is the leading cause of death among gynaecological malignancies. Extracellular matrix (ECM) can affect drug resistance by preventing the penetration of the drug into cancer cells and increased resistance to apoptosis. This study demonstrates alterations in the expression levels of ECM components and related genes in cisplatin-, doxorubicin-, topotecan-, and paclitaxel-resistant variants of the A2780 ovarian cancer cell line. Affymetrix Gene Chip Human Genome Array Strips were used for hybridisations. The genes that had altered expression levels in drug-resistant sublines were selected and filtered by scatter plots. The genes that were up- or downregulated more than fivefold were selected and listed. Among the investigated genes, 28 genes were upregulated, 10 genes were downregulated, and two genes were down- or upregulated depending on the cell line. Between upregulated genes 12 were upregulated very significantly—over 20-fold. These genes included COL1A2, COL12A1, COL21A1, LOX, TGFBI, LAMB1, EFEMP1, GPC3, SDC2, MGP, MMP3, and TIMP3. Four genes were very significantly downregulated: COL11A1, LAMA2, GPC6, and LUM. The expression profiles of investigated genes provide a preliminary insight into the relationship between drug resistance and the expression of ECM components. Identifying correlations between investigated genes and drug resistance will require further analysis.

scholarly journals Mutual Expression of ALDH1A1, LOX, and Collagens in Ovarian Cancer Cell Lines as Combined CSCs- and ECM-Related Models of Drug Resistance Development

2018 ◽  
Vol 20 (1) ◽  
pp. 54 ◽  
Author(s):  
Karolina Sterzyńska ◽  
Andrzej Klejewski ◽  
Karolina Wojtowicz ◽  
Monika Świerczewska ◽  
Marta Nowacka ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Extracellular Matrix ◽  
Drug Resistance ◽  
Cancer Cells ◽  
Cell Lines ◽  
Cancer Cell ◽  
Lysyl Oxidase ◽  
Resistant Cell ◽  
Pcr Analysis ◽  
Ovarian Cancer Cells

A major contributor leading to treatment failure of ovarian cancer patients is the drug resistance of cancer cell. CSCs- (cancer stem cells) and ECM (extracellular matrix)-related models of drug resistance are described as independently occurring in cancer cells. Lysyl oxidase (LOX) is another extracellular protein involved in collagen cross-linking and remodeling of extracellular matrix and has been correlated with tumor progression. The expression of LOX, COL1A2, COL3A1, and ALDH1A1 was performed in sensitive (A2780, W1) and resistant to paclitaxel (PAC) (A2780PR1 and W1PR2) and topotecan (TOP) (W1TR) cell lines at the mRNA (real-time PCR analysis) and protein level (Western blot and immunofluorescence analysis). The ALDH1A1 activity was measured with the ALDEFLUOR test and flow cytometry analysis. The protein expression in ovarian cancer tissues was determined by immunohistochemistry. We observed an increased expression of LOX and collagens in PAC and TOP resistant cell lines. Subpopulations of ALDH1A1 positive and negative cells were also noted for examined cell lines. Additionally, the coexpression of LOX with ALDH1A1 and COL1A2 with ALDH1A1 was observed. The expression of LOX, collagens, and ALDH1A1 was also detected in ovarian cancer lesions. In our study LOX, ALDH1A1 and collagens were found to be coordinately expressed by cells resistant to PAC (LOX, ALDH1A1, and COL1A2) or to TOP (LOX and ALDH1A1). This represents the study where molecules related with CSCs (ALDH1A1) and ECM (LOX, collagens) models of drug resistance are described as occurring simultaneously in ovarian cancer cells treated with PAC and TOP.

Elimination of Sestrin 2 Compromises Viability in Extracellular Matrix-Detached SKOV3 Ovarian Cancer Cells

2019 ◽  
Author(s):  
Yadira Gonzalez ◽  
Leann Tulisiak ◽  
Mary Philbin ◽  
Hannah Voss ◽  
Ethan Schramm ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Extracellular Matrix ◽  
Cancer Cells ◽  
Ovarian Cancer Cells

Elimination of Peroxiredoxin 1 Abrogates Proliferation and Viability in Extracellular Matrix-Detached SKOV3 Ovarian Cancer Cells

2019 ◽  
Author(s):  
Alyssa Axe ◽  
Siobhan Gilligan ◽  
Mary Green ◽  
Yadira Gonzalez ◽  
Adrian Milos ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Extracellular Matrix ◽  
Cancer Cells ◽  
Ovarian Cancer Cells ◽  
Peroxiredoxin 1

scholarly journals Membrane type 1 matrix metalloproteinase proteolytic activity in initial adhesive and invasive events of ovarian cancer metastasis

2014 ◽  
Author(s):  
◽  
Lana Bruney
Keyword(s):  
Ovarian Cancer ◽  
Extracellular Matrix ◽  
Proteolytic Activity ◽  
Ovarian Tumor ◽  
Molecular Mechanisms ◽  
Cancer Metastasis ◽  
Ectodomain Shedding ◽  
Metastatic Process

Epithelial ovarian cancer (EOC) is one of the most common gynecologic malignancies, generally developing in women over the age of forty. When EOC are diagnosed prior to metastatic dissemination, the overall 5-year survival rate is 92%; however, nearly 85% of women with EOC are diagnosed with metastasis already present, dropping the survival rate to less than 30%. EOC, arises, arguably, from the single layer of cells that cover the ovary or fallopian tube. Metastatic ovarian tumors develop once an epithelial cell transforms, inducing detachment from the primary tumor site. These shed cells travel throughout the peritoneal cavity, escaping anoikis to survive as single cells and multicellular aggregates (MCA), and metastasize intraperitoneally through adhesion to and invasion of the mesothelial cell layer covering the peritoneum, the primary microenvironment for ovarian cancer metastasis. These mesothelial cells lie atop a collagen type I-rich extracellular matrix; subsequent to the initial attachment of ovarian cancer cells, proteolytic activity catalyzes migration through the mesothelial monolayer and promotes invasion of the sub-mesothelial matrix. Elucidating the early molecular mechanisms involved in this metastatic process, specifically the adhesion of EOC cells to mesothelial cells and penetration of the associated sub-mesothelial extracellular matrix, is essential to the development of future therapeutic agents. Enzymatic activity of matrix type 1 metalloproteinase (MT1-MMP), a transmembrane proteinase that degrades interstitial collagen, has been shown to be critical to this process. MT1-MMP activity has been directly implicated in both the invasion of the sub-mesothelial collagen I matrix, and in the shedding of metastatic MCA, but the molecular mechanisms behind these events are not completely understood. Considering the well-established role of MT1-MMP in the EOC metastatic process, identification of the molecules contributing to these pro-metastatic phenotypes is critical to future understanding of EOC metastatic spread. This research investigated the initial adhesive and invasive events of ovarian cancer metastasis, as associated with MT1-MMP proteolytic activity. Specifically, the effect of MT1-MMP activity on ovarian tumor cell ectodomain shedding and the in vitro, relationship between MT1-MMP and a potential phosphorylator, integrin linked kinase (ILK), on adhesion and invasion was assessed. Investigations utilized in vitro models of homotypic and heterotypic cell-cell adhesion, meso-mimetic invasion assays, and ex vivo tissue explants. Results suggest that ILK activity may catalyze phosphorylation of MT1-MMP to promote pro-metastatic events, including strengthening of adhesive contacts, invasion of the collagen-rich sub-mesothelial matrix, and MCA formation. Additionally, MT1-MMP expression may induce MUC16/CA-125 ectodomain shedding, which may then expose integrins at the ovarian tumor cell surface for high affinity cell-cell and cell-ECM binding.

Sign in / Sign up

Export Citation Format

Share Document